Indication | Mean dose per patient (IU [range]) | Post-PCC changea in administration of: | |||
---|---|---|---|---|---|
 |  | FFP | Red blood cells | Cryoprecipitate | Platelets |
Cardiac surgery (CABG; n = 5) | 1,500 (500–4,000) | -15.8% | -63.5% | -50.0% | 20.0% |
Cardiac surgery (valve replacement; n = 2) | 500 (500 to 500) | -21.1% | -83.3% | -40.0% | -66.7% |
Other surgery (n = 9) | 850 (500 to 2,000) | -25.9% | -60.3% | -84.0% | -29.4% |
Warfarin reversal (n = 8) | 1,800 (1,000 to 4,000) | -50.0% | N/A | N/A | N/A |
All patients (n = 24) | 1,250 (500 to 4,000) | -22.7% | -63.9% | -70.5% | -22.2% |